We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+18.21%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$9.8B
AUM Growth
+$1.86B
Cap. Flow
-$1.4B
Cap. Flow %
-14.24%
Top 10 Hldgs %
73.27%
Holding
123
New
14
Increased
15
Reduced
12
Closed
2

Top Buys

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$247M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$188M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$112M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$91.9M
5
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$75.9M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$67.4M
2
XOMA
Xoma
XOMA
+$26.3M
3
AMBI
Ambit Biosciences Corp
AMBI
+$16.8M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$14.3M
5
RPRX
Repros Therapeutics Inc.
RPRX
+$6.64M

Sector Composition

Rank Sector Weight
1 Healthcare 47.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$1.12B 11.39%
9,129,231
-527,368
-5% -$67.4M
INCY icon
2
Incyte
INCY
$25.9B
$1.09B 11.08%
14,845,559
– –
GEVA
3
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$989M 10.1%
10,660,432
– –
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$895M 9.14%
27,861,720
+5,385,991
+24% +$188M
AVNR
5
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$653M 6.66%
38,513,713
+17,539,036
+84% +$247M
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$5.08B
$650M 6.64%
20,481,442
– –
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$437M 4.46%
13,656,318
+700
+0% +$22.8K
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12.9B
$336M 3.43%
3,713,950
+1,343,486
+57% +$112M
ANAC
9
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$136M 1.38%
4,204,702
– –
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.44B
$130M 1.33%
10,713,686
– –
BLCM
11
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$98.7M 1.01%
+428,373
New +$91.9M
DYAX
12
DELISTED
DYAX CORPORATION
DYAX
$86.6M 0.88%
6,157,789
– –
CERS icon
13
Cerus
CERS
$566M
$73M 0.75%
11,702,727
-237,451
-2% -$1.08M
SLXP
14
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$73M 0.75%
635,321
+626,700
+7,269% +$75.9M
VNDA icon
15
Vanda Pharmaceuticals
VNDA
$319M
$64M 0.65%
4,472,153
+100,000
+2% +$1.18M
XOMA
16
DELISTED
Xoma
XOMA
$60.8M 0.62%
846,201
-307,373
-27% -$26.3M
XNPT
17
DELISTED
XENOPORT, INC.
XNPT
$60.5M 0.62%
6,903,628
+87,851
+1% +$645K
ARAV
18
DELISTED
Aravive, Inc. Common Stock
ARAV
$51.2M 0.52%
380,291
+172,609
+83% +$20.2M
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$44.1M 0.45%
2,380,074
– –
DBVT
20
DBV Technologies
DBVT
$914M
$41.2M 0.42%
+151,923
New +$39.1M
PGNX
21
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$33.6M 0.34%
4,449,797
– –
DSCI
22
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$32.9M 0.34%
3,537,137
– –
TGTX icon
23
TG Therapeutics
TGTX
$8.31B
$32.5M 0.33%
2,050,313
– –
ACOR
24
DELISTED
Acorda Therapeutics
ACOR
$30.9M 0.32%
6,296
+18
+0.3% +$77.2K
HALO icon
25
Halozyme
HALO
$12.3B
$26.8M 0.27%
2,776,143
– –
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2014 Portfolio in Review

As of Q4 2014, Julian Baker held 123 positions worth $9.8B, up 23% from $7.94B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Julian Baker withdrew a net $1.4B in Q4 2014, closing 2 positions and reducing 12 holdings. Its most notable exit was Ambit Biosciences Corp, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 44% a quarter earlier.

Against the trend, Julian Baker opened a new position in Bellicum Pharmaceuticals, Inc. worth $98.7M.

  • Julian Baker's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 428,373 shares worth $98.7M.
  • Julian Baker added most to AVANIR PHARMACEUTICALS, INC CL A in Q4 2014, an estimated $247M increase.
  • Julian Baker's biggest Q4 2014 reduction was PHARMACYCLICS INC, cutting an estimated $67.4M.
  • Julian Baker fully exited Ambit Biosciences Corp in Q4 2014, selling an estimated $16.8M.
  • Julian Baker's ten largest holdings make up 73% of its $9.8B portfolio in Q4 2014.
  • Julian Baker opened 14 new positions and closed 2 in Q4 2014.
  • Julian Baker's portfolio value rose 23% quarter-over-quarter to $9.8B.

Based on Baker Bros. Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.